Sugi Predict

Sugi Predict / Compounds / SCHEMBL1108269

SCHEMBL1108269

SCHEMBL1108269

C1=C/COCc2cncc(c2)-c2ccnc(n2)Nc2cccc(c2)COC/1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FLT3 P36888 20/20 1.00
▸ JAK2 O60674 19/20 1.00
▸ TYK2 P29597 16/20 1.00
▸ CDK2 P24941 13/20 1.00
▸ CCNA2 P20248 8/20 0.67
▸ CCNA1 P78396 8/20 0.67
▸ JAK1 P23458 11/20 0.65
▸ JAK3 P52333 5/20 0.64
▸ HDAC3 O15379 1/20 0.56
▸ HDAC4 P56524 1/20 0.56
▸ HDAC1 Q13547 1/20 0.56
▸ HDAC7 Q8WUI4 1/20 0.56
▸ HDAC2 Q92769 1/20 0.56
▸ HDAC10 Q969S8 1/20 0.56
▸ HDAC11 Q96DB2 1/20 0.56
▸ HDAC8 Q9BY41 1/20 0.56
▸ HDAC6 Q9UBN7 1/20 0.56
▸ HDAC9 Q9UKV0 1/20 0.56
▸ HDAC5 Q9UQL6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29617551 0.90 FLT3 (0.82) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL20322485 0.90 FLT3 (0.82) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL824098 0.89 FLT3 (1.00) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL1108225 0.82 JAK2 (0.71) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL1108219 0.82 JAK2 (0.71) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL823902 0.81 FLT3 (0.67) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL20322488 0.81 JAK2 (0.79) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL824044 0.80 FLT3 (1.00) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL824054 0.80 FLT3 (1.00) FLT3JAK2TYK2CDK2CCNA2
SCHEMBL823837 0.80 FLT3 (0.69) FLT3JAK2TYK2CDK2CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135227-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2021-10-05 — — US disclosed
EP-3854402-A1 TREATMENT OR PREVENTION OF TRANSPLANT REJECTION CTI Biopharma Corp. (US) 2021-07-28 — — EP disclosed
US-20210069199-A1 METHODS OF TREATING TRANSPLANT REJECTION SOBI, INC. 2021-03-11 — — US disclosed
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2020-03-05 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
EP-1951729-B1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS INC (US) 2014-06-25 — — EP disclosed
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS, INC. (US) 2013-07-04 — — US disclosed
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS, INC. (US) 2013-07-04 — — US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
WO-2007058627-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD (SG) 2007-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210069199-A1 METHODS OF TREATING TRANSPLANT REJECTION JAK1, JAK2, JAK3 FLT3 50/4885JAK2 2/4885TYK2 34/4885
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 FLT3 645/4885JAK2 468/4885TYK2 960/4885
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 FLT3 645/4885JAK2 468/4885TYK2 960/4885
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 FLT3 645/4885JAK2 468/4885TYK2 960/4885
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 FLT3 645/4885JAK2 468/4885TYK2 960/4885
US-11135227-B2 Oxygen linked pyrimidine derivatives DPYD, TK2, TK1 FLT3 645/4885JAK2 468/4885TYK2 960/4885
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 FLT3 645/4885JAK2 468/4885TYK2 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.